Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 5.0% Today

What is Thermo Fisher Scientific Inc?

Thermo Fisher Scientific Inc (TMO) is a leading company in the scientific research and healthcare industry, known for its innovative solutions and services.

Why is Thermo Fisher Scientific Inc going up?

TMO stock is up 5.0% on Apr 14, 2026 14:41

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

TMO Price Chart

TMO Technical Analysis

TMO News

Qiagen N.V. stock (NL0012169213): Why does its molecular diagnostics edge matter more now for U.S. investors?

The article discusses why Qiagen N.V.'s molecular diagnostics capabilities are increasingly relevant for U.S. investors, highlighting the company's "sample-to-insight" business model and its comprehensive portfolio of tools. It covers key products, industry drivers, competitive strengths, and analyst views, while also addressing potential risks such as supply chain vulnerabilities and regulatory hurdles. Qiagen's focus on precise genomic testing and personalized medicine positions it as a key player in an evolving biotech landscape.

https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-nl0012169213-why-does-its-molecular-diagnostics-edge/69143141

Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities

Thermo Fisher Scientific's PPD clinical research business has announced a strategic collaboration with HealthVerity to enhance data-driven clinical development and evidence generation for biopharma sponsors. This agreement grants PPD enterprise-level access to HealthVerity's extensive TaXOnomy® claims dataset, covering over 270 million de-identified patient lives in the U.S. The partnership aims to provide deeper insights into disease patterns, treatment, and provider activity, strengthening PPD's data and AI-driven services and improving trial feasibility, optimization, recruitment, and real-world evidence generation.

https://www.biospace.com/press-releases/thermo-fisher-scientifics-ppd-clinical-research-business-collaborates-with-healthverity-to-expand-real-world-data-capabilities

Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Rebound

Charles River Laboratories (CRL) has seen recent share price gains, up 15% over the past month, but is down 11.9% year-to-date. While Simply Wall St's narrative suggests CRL is 43.1% undervalued with a fair value of $313.61, their DCF model indicates it is overvalued at its current price of $178.34, with an estimated fair value of $134.83. The article highlights CRL's recent acquisition of a Cambodian primate supplier to secure NHP access, revealing a bottleneck in drug development, but also points to a recent net income loss and reliance on sensitive research as risks.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/assessing-charles-river-laboratories-crl-valuation-after-rec-2

Thermo Fisher Scientific Inc (TMO) Shares Surge 3.6% -- What GF Score of 88 Tells Investors

Thermo Fisher Scientific Inc (TMO) shares rose 3.6% today, with a current price of $514.23, indicating an 11.1% undervaluation compared to its GF Value™ of $578.18. The company boasts a strong GF Score™ of 88/100, though recent insider selling of $8.2 million without corresponding purchases suggests a need for investor caution. Despite the undervaluation and strong overall performance metrics like profitability and growth, the insider activity could signal potential challenges in the near term.

https://www.gurufocus.com/news/8790548/thermo-fisher-scientific-inc-tmo-shares-surge-36-what-gf-score-of-88-tells-investors

Thermo Fisher Scientific (TMO) Valuation Check As New PRECISE Collaboration Targets Long Term Precision Medicine Growth

Thermo Fisher Scientific (TMO) recently announced a collaboration with Precision Health Research, Singapore for the PRECISE-SG100K biobank, aiming to advance precision medicine. Despite a mixed stock performance with a recent gain but year-to-date decline, analysts value the stock at a higher target price than its current trading price. The article discusses two valuation narratives: one suggesting it's undervalued based on long-term demand, and another flagging caution due to its P/E ratio.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-valuation-check-as-new-precise

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.2% Today

Thermo Fisher Scientific Inc Price History

01.07.2025 - TMO Stock was down 5.1%

• The decline in Thermo Fisher Scientific's stock today may be linked to the adoption of a bearish stance by influential investors, as reflected in options trading activities.
• While TMO has consistently outperformed the market in the long run, short-term market sentiment and investor behavior can impact daily fluctuations.
• Investors might be capitalizing on gains or adjusting their positions in response to prevailing market conditions or internal company developments, influencing the stock's downward trajectory today.
• It is crucial for investors to assess both TMO's long-term growth prospects and the short-term market dynamics to make well-informed investment choices.

29.00.2026 - TMO Stock was down 5.2%

• Thermo Fisher (TMO) experienced a bearish movement despite reporting better-than-expected Q4 CY2025 results, with revenue surpassing analyst estimates and strong performance in its Life Sciences Solutions segment.
• The stock might have faced downward pressure due to profit-taking by investors following the immediate stock increase post-earnings report.
• The overall market sentiment could have been influenced by broader market conditions or sector rotation, leading to the bearish movement in TMO's stock price today.
• It's possible that investors were expecting even stronger guidance or future outlook from the company, causing some disappointment and resulting in the bearish market movement.

30.08.2025 - TMO Stock was up 3.8%

• The positive market response to TMO's bond offering suggests investor confidence in the company's financial stability.
• The continued bullish interest from financial institutions and traders signals strong belief in Thermo Fisher Scientific's growth potential.
• Overall, TMO's bullish performance today could be linked to the successful bond offering and positive market sentiment.

02.00.2026 - TMO Stock was up 2.2%

• The global single-use bioprocessing products market is expected to witness substantial growth, with Thermo Fisher Scientific Inc. playing a significant role in the industry's advancement, contributing to the optimistic market trends.
• Noteworthy increases in stakes by Allspring Global Investments Holdings LLC and Ninety One UK Ltd in TMO reflect a growing confidence in the company's future, potentially influencing a rise in the stock's value.
• Despite recent significant insider sales, the company's impressive quarterly earnings report surpassing expectations, coupled with the initiation of a new stock buyback program and quarterly dividend declaration, have likely bolstered investor trust in TMO.
• The collective institutional interest and portfolio adjustments by different investment entities indicate a favorable outlook for TMO, aligning with the current bullish market movement.

18.11.2025 - TMO Stock was down 2.4%

• The decline in TMO stock may be linked to profit-taking by institutional investors actively trading the stock.
• Despite positive updates on strong quarterly earnings and a $5 billion share buyback program, concerns arose among investors due to insider selling by the CEO and COO, potentially contributing to the stock's downward trend.
• Weak performance by West Pharmaceutical Services (WST) in the healthcare sector could have also impacted investor sentiment towards TMO, as some may have shifted away from underperforming healthcare stocks.
• In sum, today's bearish movement in TMO stock seems influenced by profit-taking, insider selling concerns, and broader sector trends affecting investor outlook.

23.06.2025 - TMO Stock was up 11.9%

• Financial giants and deep-pocketed investors have shown a bullish sentiment towards Thermo Fisher Scientific, with a majority of traders leaning towards a positive outlook on the stock.
• The upcoming second-quarter earnings report, especially focusing on the Analytical Instruments segment, has generated optimism and interest among investors.
• The increased bullish options trading activity suggests that market players are anticipating positive growth and performance from Thermo Fisher Scientific in the near future.

23.06.2025 - TMO Stock was up 12.4%

• Q2 earnings and revenues of Thermo Fisher Scientific exceeded expectations, propelled by successful product launches and robust segment growth, resulting in a notable increase in the stock price.
• Notable bullish sentiment was observed in the options trends for TMO, with a majority of traders expressing optimism about the stock.
• Investors are placing emphasis on the growth prospects of Thermo Fisher's Analytical Instruments segment, foreseeing its positive impact on performance in the upcoming quarters.
• The optimistic outlook from major investors towards TMO, reflected through options activity, likely played a role in the stock's favorable market trajectory today.

12.01.2026 - TMO Stock was down 5.2%

• Varma Mutual Pension Insurance Co and Cornerstone Investment Partners LLC increased their holdings in TMO, showing confidence in the company's future prospects.
• ING Groep NV and Atria Investments Inc reduced their stakes in TMO, possibly due to profit-taking or portfolio rebalancing.
• The initiation of a $5 billion stock repurchase plan by Thermo Fisher Scientific may have influenced market sentiment, signaling management's belief in the company's undervaluation.
• Despite the mixed institutional activity and insider sales, analysts maintain a "Moderate Buy" rating for TMO, with an average price target of $633.68, reflecting positive quarterly earnings and growth potential.

22.06.2025 - TMO Stock was up 5.5%

• Thermo Fisher Scientific is set to report its Q2 earnings, with a focus on its Analytical Instruments segment, indicating potential positive performance in this area.
• The bullish approach adopted by deep-pocketed investors towards TMO, as reflected in the options market, could be driving the upward momentum in the stock price.
• The market seems optimistic about Thermo Fisher's growth prospects, especially with new technological launches in key segments, fueling investor confidence and contributing to the bullish movement in the stock today.

14.03.2026 - TMO Stock was up 5.0%

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

10.06.2025 - TMO Stock was up 4.6%

• Despite negative moves by financial institutions and stock downgrades by analysts, Thermo Fisher Scientific (TMO) saw a significant rise in stock price.
• Unusual options trading, displaying a mix of bullish and bearish trends, likely contributed to the stock's fluctuating price.
• Divergent opinions among traders and analysts may have caused market uncertainty, prompting increased buying activity and driving up the stock price.
• Investors possibly prioritized the company's strong fundamentals and future growth potential, overshadowing short-term bearish signals from analysts and options trades.

01.09.2025 - TMO Stock was up 9.2%

• The stock of Thermo Fisher Scientific showed a strong upward trend today, likely influenced by a noteworthy Power Inflow alert, reflecting optimistic sentiment from institutional and retail investors.
• The company's decision to initiate a four-part bond offering in anticipation of a potential government shutdown might have also played a part in the positive trend, demonstrating proactive financial preparation and stability.
• The optimistic actions of financial institutions and the prevailing bullish sentiment among traders regarding TMO all contributed to the favorable momentum, underscoring confidence in the company's future prospects.